In the context of the shock and kill strategy, MVC administration as an LRA would retain its antiviral efficacy that becomes evident when administered before infection, counteracting productive HIV infection in memory CD4 T cells without promoting an increase in infection levels. Here, CD4 is linked to HIV infectious disease.